How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,003 results for

Incremental Cost Effectiveness Ratio

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology (PubMed)

Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology Incremental cost-effectiveness ratios (ICERs) are used to assess the value for money of new drugs. Many believe that ICERs for drugs that treat rare diseases are much higher than those of common drugs. Our objective was to compare the proportion of ICERs that are cost effective for rare and common cancers.We used the Tufts Medical Center Cost-Effectiveness Analysis (CEA) Registry (...) to identify cost-effectiveness studies of pharmaceutical interventions for cancers. Studies that assessed FDA-approved 'orphan drugs' were categorized as assessing rare cancers. The proportion of common and rare cancer drugs that were cost effective at various ICER thresholds were compared along with study characteristics. Logistic regressions were conducted to assess important predictors of cost effectiveness.We identified 303 studies that reported 701 ICERs. Seventy nine percent (n = 240) of studies

Full Text available with Trip Pro

2017 PharmacoEconomics open

2. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY? (PubMed)

What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY? The National Institute for Health and Care Excellence has recently proposed that company submissions with a base-case incremental cost-effectiveness ratio (ICER) of less than £10,000/quality-adjusted life-year (QALY) might be eligible for a "fast-track" appraisal.To explore

Full Text available with Trip Pro

2018 Value in Health

3. Incremental Cost Effectiveness Ratio

Incremental Cost Effectiveness Ratio Incremental Cost Effectiveness Ratio Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Incremental (...) Cost Effectiveness Ratio Incremental Cost Effectiveness Ratio Aka: Incremental Cost Effectiveness Ratio , ICER From Related Chapters II. Definition: Incremental Cost Effectiveness Ratio (ICER) Based on cost for an outcome utility or value (e.g. ) Cost effectiveness can be determined by comparing ICER to a willingness to pay III. Technique Given Two strategies: 1 and 2 (e.g. treatment and no treatment) Calculation Incremental Cost Effectiveness Ratio (ICER) = Incremental_Cost

2018 FP Notebook

4. Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis (PubMed)

Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis This study responds to a request in the National Institute for Health and Care Excellence (NICE) guidance to assess the impact of using alternative sources of utility values, applied to multiple sclerosis (MS).Incremental cost-effectiveness ratios (ICERs) were calculated using utility values based on UK and Dutch values of EQ-5D, two UK mappings and one Dutch mapping of EQ (...) of the model than did EQ-5D. The ICER of glatiramer acetate with EQ-5D was US$182,291 for The Netherlands and US$153,476 for the UK. Ratios for mapped and condition-specific utilities were between 20 and 60 % higher.The overestimation of quality of life of patients with MS by mapped EQ-5D or condition-specific utility values, relative to observed EQ-5D, increases the ICER substantially in a lifetime Markov model.

Full Text available with Trip Pro

2016 PharmacoEconomics

5. Possible Impact of Incremental Cost-Effectiveness Ratio (ICER) on Decision Making for Cancer Screening in Hong Kong: A Systematic Review. (PubMed)

Possible Impact of Incremental Cost-Effectiveness Ratio (ICER) on Decision Making for Cancer Screening in Hong Kong: A Systematic Review. The aim of this paper was to critically review the literature on the cost effectiveness of cancer screening interventions, and examine the incremental cost-effectiveness ratios (ICERs) that may influence government recommendations on cancer screening strategies and funding for mass implementation in the Hong Kong healthcare system.We conducted a literature (...) review of cost-effectiveness studies in the Hong Kong population related to cancer screening published up to 2015, through a hand search and database search of PubMed, Web of Science, Embase, and OVID Medline. Binary data on the government's decisions were obtained from the Cancer Expert Working Group, Department of Health. Mixed-effect logistic regression analysis was used to examine the impact of ICERs on decision making. Using Youden's index, an optimal ICER threshold value for positive decisions

2016 Applied Health Economics and Health Policy

6. Economic analysis of three interventions of different intensity in improving school implementation of a government healthy canteen policy in Australia: costs, incremental and relative cost effectiveness. (PubMed)

Economic analysis of three interventions of different intensity in improving school implementation of a government healthy canteen policy in Australia: costs, incremental and relative cost effectiveness. No evaluations of the cost or cost effectiveness of interventions to increase school implementation of food availability policies have been reported. Government and non-government agency decisions regarding the extent of investment required to enhance school implementation of such policies (...) was undertaken. Secondly, an indirect comparison of the trials was undertaken to determine the most cost-effective of the three strategies. The economic analysis was based on the cost of delivering the interventions by health service delivery staff to increase the proportion of schools 'adherent' with the policy.The total costs per school were $166,971, $70,926 and $75,682 for the high, medium and low intensity interventions respectively. Compared to usual support, the cost effectiveness ratios for each

Full Text available with Trip Pro

2018 BMC Public Health

7. Incremental Cost-Effectiveness of Aspiration Therapy vs Bariatric Surgery and No Treatment for Morbid Obesity. (PubMed)

Incremental Cost-Effectiveness of Aspiration Therapy vs Bariatric Surgery and No Treatment for Morbid Obesity. Despite its recent approval by the US Food and Drug Administration and Health Canada, aspiration therapy-one of the latest weight loss treatments-remains controversial. Critics have expressed concerns that the therapy could lead to bulimia and other binge eating disorders. Meanwhile, proponents argue that the therapy is less invasive, reversible, and cheaper than bariatric surgery (...) . Cost-effectiveness of this therapy, however, is not yet established.We developed a Markov model to estimate the incremental cost-effectiveness of aspiration therapy relative to 2 most common bariatric surgery procedures (gastric bypass and sleeve gastrectomy) and no treatment over a lifetime horizon. Costs were estimated from the health system's perspective using US data. Effectiveness was measured in terms of quality-adjusted life-years (QALYs).Despite being a cheaper procedure than bariatric

2019 American Journal of Gastroenterology

8. Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data. (PubMed)

(standard error = £28.50) for metabolic and cardioprotective medication. For ADDITION-UK, over the 10-, 20-, and 30-year time horizon, adjusted incremental quality-adjusted life-years (QALYs) were 0.014, 0.043, and 0.048, and adjusted incremental costs were £1,021, £1,217, and £1,311, resulting in incremental cost-effectiveness ratios of £71,232/QALY, £28,444/QALY, and £27,549/QALY, respectively. Respective incremental cost-effectiveness ratios for ADDITION-Cambridge were slightly higher.The incremental (...) Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data. There is uncertainty about the cost effectiveness of early intensive treatment versus routine care in individuals with type 2 diabetes detected by screening.To derive a trial-informed estimate of the incremental costs of intensive treatment as delivered in the Anglo-Danish-Dutch Study of Intensive

Full Text available with Trip Pro

2017 Value in Health

9. Incremental clinical effectiveness and cost effectiveness of providing supervised physiotherapy in addition to usual medical care in patients with osteoarthritis of the hip or knee: 2-year results of the MOA randomised controlled trial. (PubMed)

Incremental clinical effectiveness and cost effectiveness of providing supervised physiotherapy in addition to usual medical care in patients with osteoarthritis of the hip or knee: 2-year results of the MOA randomised controlled trial. To investigate the clinical- and cost-effectiveness at 2-year follow-up of providing individual, supervised exercise physiotherapy and/or manual physiotherapy in addition to usual medical care.People with hip or knee osteoarthritis meeting the American College (...) of Rheumatology clinical diagnostic criteria were randomised (1:1, concealed, assessor-blinded) to four groups: usual medical care; supervised exercise physiotherapy; manual physiotherapy; or combined exercise and manual physiotherapy. Physiotherapy group participants were provided 10 50-min treatment sessions including booster sessions at 4 and 13 months, in addition to usual care. The primary outcome at 2-year follow-up was incremental cost-utility ratio (ICUR) of each physiotherapy intervention in addition

2018 Osteoarthritis and Cartilage

10. Incremental cost and cost-effectiveness of low-dose, high-frequency training in basic emergency obstetric and newborn care as compared to status quo: part of a cluster-randomized training intervention evaluation in Ghana (PubMed)

key parameters.For the 40 health facilities included in the evaluation, the total LDHF training cost was $823,134. During the follow-up period after the first LDHF training-1 year at each participating facility-approximately 544 lives were saved. With deterministic calculation, these findings translate to $1497.77 per life saved or $53.07 per DALY averted. Probabilistic sensitivity analysis, with mean incremental cost-effectiveness ratio of $54.79 per DALY averted ($24.42-$107.01), suggests (...) Incremental cost and cost-effectiveness of low-dose, high-frequency training in basic emergency obstetric and newborn care as compared to status quo: part of a cluster-randomized training intervention evaluation in Ghana Low-dose, high-frequency (LDHF) training is a new approach best practices to improve clinical knowledge, build and retain competency, and transfer skills into practice after training. LDHF training in Ghana is an opportunity to build health workforce capacity in critical areas

Full Text available with Trip Pro

2017 Globalization and health

11. Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA

Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA | BMJ Evidence-Based Medicine We use cookies to improve our (...) * Password * your user name or password? You are here Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA Article Text Therapeutics Cost-effectiveness analysis Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics

2010 Evidence-Based Medicine (Requires free registration)

12. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of different treatments for patients with severe or very severe chronic obstructive pulmonary disease. The authors concluded that the UK clinical practice was cost-effective

Full Text available with Trip Pro

2012 NHS Economic Evaluation Database.

13. Incremental cost-effectiveness of various monthly doses of vardenafil

presented in line graphs. Results The QALYs gained were 10.13 for no vardenafil; 11.36 for four doses a month; 11.50 for six doses a month; and 11.57 for eight doses a month. The monthly costs were zero for no vardenafil; $707.70 for four doses; $1,061.60 for six doses; and $1,415.50 for eight doses. The incremental cost per QALY gained for four doses, compared with none, was $576. The incremental cost-effectiveness ratio (ICER) for six doses, compared with four, was $2,585. The ICER for eight doses (...) Incremental cost-effectiveness of various monthly doses of vardenafil Incremental cost-effectiveness of various monthly doses of vardenafil Incremental cost-effectiveness of various monthly doses of vardenafil Aspinall SL, Smith KJ, Cunningham FE, Good CB Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

14. Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore. (PubMed)

the mutation. Singapore-specific costs and prevalence of MODY obtained from local studies and utility values sourced from the literature are used to populate the model.The algorithm-driven MODY testing strategy has an incremental cost-effectiveness ratio of US$93 663 per quality-adjusted life year relative to the no testing strategy. If the price of genetic testing falls from US$1050 to US$530 (a 50% decrease), it will become cost-effective.Our proposed algorithm-driven testing strategy for MODY is not yet (...) Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore. Offering genetic testing for Maturity Onset Diabetes of the Young (MODY) to all young patients with type 2 diabetes has been shown to be not cost-effective. This study tests whether a novel algorithm-driven genetic testing strategy for MODY is incrementally cost-effective relative to the setting of no testing.A decision tree was constructed

2017 Journal of Medical Genetics

15. Multidisciplinary Treatment Programs for Patients with Chronic Non-Malignant Pain: A Review of Clinical Effectiveness, Cost-effectiveness, and Guidelines – An Update

in an incremental cost-effectiveness ratio exceeding standard willingness-to-pay thresholds. Findings from the current report are consistent with those from the 2017 CADTH Rapid Response report.2 Evidence regarding optimal pain management services suggests that there is a benefit from moving beyond the only use of medication to more comprehensive programs. However, further research is needed to identify the type of components and combinations that would provide optimal benefits for patients with chronic pain (...) Multidisciplinary Treatment Programs for Patients with Chronic Non-Malignant Pain: A Review of Clinical Effectiveness, Cost-effectiveness, and Guidelines – An Update Multidisciplinary Treatment Programs for Patients with Chronic Non-Malignant Pain: A Review of Clinical Effectiveness, Cost-effectiveness, and Guidelines – An Update | CADTH.ca Find the information you need Multidisciplinary Treatment Programs for Patients with Chronic Non-Malignant Pain: A Review of Clinical Effectiveness, Cost

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Disinfection of Multi-Use Ocular Equipment for Ophthalmological Procedures: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

bleach as a disinfection technique of tonometers. Using alcohol swabs as a base case, the cost-effective analysis demonstrated that the incremental cost-effectiveness ratio for peroxide bleach was $12,152 Canadian dollars per epidemic keratoconjunctivitis averted. The identified guideline recommends that ophthalmic equipment be cleaned immediately as per the manufacturer’s written instruction of use based on strong evidence. Additional recommendations were general and with respect to how the cleaning (...) Disinfection of Multi-Use Ocular Equipment for Ophthalmological Procedures: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Disinfection of Multi-Use Ocular Equipment for Ophthalmological Procedures: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Disinfection of Multi-Use Ocular Equipment for Ophthalmological Procedures: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Disinfection

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Management of type 2 diabetes with Fixed-Ratio combination insulin degludec/liraglutide (IDEGLIRA) versus Basal-Bolus therapy (INSULIN GLARGINE U100 PLUS INSULIN ASPART): A Short-Term Cost-Effectiveness analysis in the UK setting. (PubMed)

was associated with an improvement of 0.05 quality-adjusted life years (QALYs) versus BBT, due to reductions in non-severe hypoglycaemic episodes and BMI with IDegLira. Costs were higher with IDegLira by GBP 303 per patient, leading to an incremental cost-effectiveness ratio (ICER) of GBP 5924 per QALY gained for IDegLira versus BBT. ICERs remained below GBP 20 000 per QALY gained across a range of sensitivity analyses.IDegLira is a cost-effective alternative to BBT with insulin glargine U100 plus insulin (...) Management of type 2 diabetes with Fixed-Ratio combination insulin degludec/liraglutide (IDEGLIRA) versus Basal-Bolus therapy (INSULIN GLARGINE U100 PLUS INSULIN ASPART): A Short-Term Cost-Effectiveness analysis in the UK setting. To evaluate the cost-effectiveness of IDegLira versus basal-bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.A Microsoft Excel model was used to evaluate the cost-utility of IDegLira

Full Text available with Trip Pro

2018 obesity & metabolism

18. A review of the evidence base for modelling the costs of overweight, obesity and diet-related illness for Scotland, and critical appraisal of the cost-effectiveness evidence base for population wide interventions to reduce overweight, obesity and diet-rel

A review of the evidence base for modelling the costs of overweight, obesity and diet-related illness for Scotland, and critical appraisal of the cost-effectiveness evidence base for population wide interventions to reduce overweight, obesity and diet-rel 1 A review of the evidence base for modelling the costs of overweight, obesity and diet-related illness for Scotland, and critical appraisal of the cost-effectiveness evidence base for population wide interventions to reduce overweight (...) of methods 10 1.4 Structure of the report 10 2 Evidence base relating to the costs of overweight, obesity and diet-related illness 11 2.1 Overview of cost of illness methods 11 Figure 1 Overview of costs 12 2.2 Literature search 14 Figure 2 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta- Analyses) flow chart of cost of illness studies 16 Included 16 Eligibility 16 Screening 16 Identification 16 2.3 Results and critical appraisal 17 2.4 Summary and conclusions 22 3 Cost-effectiveness

2017 Health Economics Research Unit

19. Incremental cost-utility analysis of deep anterior lamellar keratoplasty compared with penetrating keratoplasty for the treatment of keratoconus

and penetrating keratoplasty were highly cost-effective, and DALK had a low cost-utility ratio and was preferred over penetrating keratoplasty. The methods were valid and transparent, which makes the authors’ conclusions robust, but there were some weaknesses in the designs of the main clinical sources. Type of economic evaluation Cost-utility analysis Study objective The objective was to assess the cost-effectiveness of deep anterior lamellar keratoplasty (DALK; corneal transplant) compared with penetrating (...) with penetrating keratoplasty, and 2.8 with DALK. The incremental cost per QALY gained was SGD 3,750 with penetrating keratoplasty, over no treatment, and SGD 3,025 with DALK over penetrating keratoplasty. The sensitivity analysis showed that the base-case findings were robust to variations in the model inputs. When the operation times for penetrating keratoplasty and DALK were assumed to be equal, DALK dominated penetrating keratoplasty, as it was less costly and more effective. A threshold 20-year graft

2011 NHS Economic Evaluation Database.

20. Cardiovascular Magnetic Resonance Imaging—Incremental Value in a Series of 361 Patients Demonstrating Cost Savings and Clinical Benefits: An Outcome-Based Study (PubMed)

patients (pts) who underwent CMR exams was conducted. Indications for CMR were tabulated for appropriateness criteria. Components of the CMR exam were identified along with evidence of clinical impact. The cost of each CMR exam was ascertained along with cost savings attributable to the CMR exam for calculation of an incremental cost-effectiveness ratio. A total of 354 of 361 pts (98%) had diagnostic quality studies. Of the 361 pts, 350 (97%) had at least 1 published Appropriateness Criterion for CMR (...) Cardiovascular Magnetic Resonance Imaging—Incremental Value in a Series of 361 Patients Demonstrating Cost Savings and Clinical Benefits: An Outcome-Based Study This study was designed to assess the clinical impact and cost-benefit of cardiovascular magnetic resonance imaging (CMR). In the face of current health care cost concerns, cardiac imaging modalities have come under focused review. Data related to CMR clinical impact and cost-benefit are lacking.Retrospective review of 361 consecutive

Full Text available with Trip Pro

2017 Clinical Medicine Insights. Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>